---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-023509"
form_type: "8-K"
ticker: "BDSX"
cik: "0001439725"
company_name: "BIODESIX INC"
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:26:05.955529+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biodesix Q4 revenue $14.7M (+53% YoY); guides FY2024 revenue $65-$68M

## Summary
- Full-year 2023 revenue $49.1M, +28% YoY; Lung Diagnostic test volume up 65%.
- Q4 gross margin 77% vs 66% a year ago; net loss improved 55% to $9.1M.
- FY2023 Adjusted EBITDA loss $32.7M, improved 24% YoY.
- Cash $26.3M at Dec 31, 2023; drew $10M second tranche from Perceptive term loan.
- FY2024 revenue guidance $65-$68M, representing 32%-39% YoY growth.

## SEC filing metadata
- accession: 0000950170-24-023509
- form_type: 8-K
- ticker: BDSX
- cik: 0001439725
- company_name: BIODESIX INC
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439725/000095017024023509/0000950170-24-023509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439725/000095017024023509/bdsx-20240301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-023509
- JSON: https://secwatch.observer/filing/0000950170-24-023509.json
- Plain text: https://secwatch.observer/filing/0000950170-24-023509.txt

## Key facts
- Earnings Releases
  BIODESIX INC reported the fourth quarter and year ended December 31, 2023 results: revenue $14.7 million and $49.1 million for the fourth quarter and fiscal 2023, respectively, net income Net loss of $9.1 million and $52.1 million for the fourth quarter and fiscal 2023, respectively. Guidance reaffirmed.
  - Period: the fourth quarter and year ended December 31, 2023
  - Revenue: $14.7 million and $49.1 million for the fourth quarter and fiscal 2023, respectively
  - Net income: Net loss of $9.1 million and $52.1 million for the fourth quarter and fiscal 2023, respectively
  - Guidance: reaffirmed
  - Result: reported results
  source text: Biodesix, Inc. (the Company) issued a press release announcing the financial and operating results of the Company for the fourth quarter and year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439725/000095017024023509/0000950170-24-023509-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.